- RemoPro™ (treprostinil prodrug)
-
Product
RemoPro™
(treprostinil prodrug)Therapeutic Platform
Remodulin®Targeted Indication
Pulmonary Hypertension (PH) WHO Group 1 (PAH)Status
Phase 1Prodrug of treprostinil that is being developed to reduce site pain associated with subcutaneous delivery of treprostinil.
LEARN MORE Close
Menu